Western Pennsylvania's trusted news source
Mylan agrees to pay $30M in SEC EpiPen settlement | TribLIVE.com
Allegheny

Mylan agrees to pay $30M in SEC EpiPen settlement

Associated Press
1732691_web1_AP_18053608066135
AP
Mylan has agreed to pay $30 million in a settlement tied to its failure to tell investors about a Justice Department investigation into whether the company overcharged Medicaid for the EpiPen.

Mylan has agreed to pay $30 million in a settlement tied to its failure to tell investors about a Justice Department investigation into whether the company overcharged Medicaid for the EpiPen.

The Securities and Exchange Commission said Friday that Mylan NV classified the EpiPen as a “generic” drug under the Medicaid drug rebate program. This led to the pharmaceutical company paying much lower rebates to the government than if the EpiPen had been classified as a “branded” drug.

Mylan, based in Washington County, had disclosed in July that it had reached an agreement-in-principle with the SEC on the matter. The company said in a statement Friday that it neither admits nor denies the SEC’s allegations.

In July, Pfizer, the country’s largest drug-maker, announced it would absorb Mylan. The two pharmaceutical companies said they will combine Mylan, valued at $10 billion, with Pfizer’s Upjohn, which sells name brands from Viagra to the cholesterol medication Lipitor that have lost patent protection.

Remove the ads from your TribLIVE reading experience but still support the journalists who create the content with TribLIVE Ad-Free.

Get Ad-Free >

Categories: Business | Local | Allegheny | Top Stories
Content you may have missed